Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other Accumulated Expenses (2020 - 2023)

Barinthus Biotherapeutics (BRNS) has disclosed Other Accumulated Expenses for 4 consecutive years, with $1.3 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Other Accumulated Expenses fell 50.17% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Sep 2023, down 50.17%, and an annual FY2022 reading of $932000.0, down 25.56% over the prior year.
  • Other Accumulated Expenses was $1.3 million for Q3 2023 at Barinthus Biotherapeutics, up from $638000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.6 million in Q3 2022 and bottomed at $46000.0 in Q2 2021.
  • Average Other Accumulated Expenses over 4 years is $922818.2, with a median of $932000.0 recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 2091.3% in 2022, then tumbled 50.17% in 2023.
  • Year by year, Other Accumulated Expenses stood at $266000.0 in 2020, then soared by 370.68% to $1.3 million in 2021, then fell by 25.56% to $932000.0 in 2022, then soared by 41.09% to $1.3 million in 2023.
  • Business Quant data shows Other Accumulated Expenses for BRNS at $1.3 million in Q3 2023, $638000.0 in Q2 2023, and $932000.0 in Q4 2022.